phenobarbital has been researched along with Cytomegalovirus Infections in 1 studies
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.
Cytomegalovirus Infections: Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kraft, WK | 1 |
| Dysart, K | 1 |
| Greenspan, JS | 1 |
| Gibson, E | 1 |
| Kaltenbach, K | 1 |
| Ehrlich, ME | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Buprenorphine for the Treatment of Neonatal Abstinence Syndrome[NCT00521248] | Phase 1 | 60 participants (Anticipated) | Interventional | 2004-04-30 | Completed | ||
| Prospective Randomized Blinded Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)[NCT04455802] | Phase 3 | 0 participants (Actual) | Interventional | 2020-10-01 | Withdrawn (stopped due to termination of funding) | ||
| A Randomized, Active-Control, Double-Blind, Double-Dummy Clinical Trial Comparing Sublingual Buprenorphine And Morphine Solution For The Treatment Of Neonatal Opioid Abstinence Syndrome[NCT01452789] | Phase 3 | 63 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This endpoint will compare length of stay in the hospital (in days) using sublingual buprenorphine or morphine solution. (NCT01452789)
Timeframe: Duration of hospital stay is an expected average of 5 weeks.
| Intervention | days (Median) |
|---|---|
| Sublingual Buprenorphine | 21 |
| Oral Morphine | 33 |
This endpoint will compare length of treatment (in days) using sublingual buprenorphine or oral morphine solution. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | days (Median) |
|---|---|
| Sublingual Buprenorphine | 15 |
| Oral Morphine | 28 |
Adverse events will be collected, graded by severity, and assessed for causality referent to study drug. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sublingual Buprenorphine | 7 |
| Oral Morphine | 8 |
This endpoint will compare requirement number of patients who require use of supplemental phenobarbital. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | participants (Number) |
|---|---|
| Sublingual Buprenorphine | 5 |
| Oral Morphine | 7 |
1 trial available for phenobarbital and Cytomegalovirus Infections
| Article | Year |
|---|---|
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |